Medicus Pharma (MDCX) risk factors, FY2025 10-K

Risks Relating to Our Business

1. 01We have a limited operating history, which may make it difficult to evaluation our current business and predict our future performance
2. 02We have a novel technology with uncertain market acceptance
3. 03The University of Pittsburgh may terminate our license agreement in certain circumstances
4. 04We may not successfully integrate Antev into our business and operations or successfully develop Teverelix
5. 05Certain of our intellectual property is held under third-party licenses
6. 06Our technology may not be successful for its intended use
7. 07Substantial doubt exists about the Company's ability to continue as a going concern and if the Company is unable to obtain additional financing from outside sources and/or eventually generate enough revenues, it may be forced to curtail or discontinue its operations
8. 08Future technology will require regulatory approval, which is costly and we may not be able to obtain it and we may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications
9. 09Changes in methods of manufacturing or formulation may result in additional costs or delay
10. 10We rely on external contract research organizations to provide clinical and nonclinical research services and agreements with these organizations of which one agreement is currently in place
11. 11If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell the Products, if approved, we may be unable to generate any product revenue
12. 12We rely on key personnel
13. 13We may not be able to successfully execute our business strategy
14. 14We will require additional financing in the future, which may not be available on favorable terms or at all
15. 15We have had negative operating cash flows since inception and expect to incur losses for the foreseeable future
16. 16We are in a highly competitive industry which is continuously evolving with technological changes
17. 17Our future success will depend on our ability to continually enhance and develop the Products
18. 18If we are unable, for any reason, to enhance, develop, introduce and sell new products in a timely manner, or at all, in response to changing market conditions or customer requirements or otherwise, our business would be harmed
19. 19A variety of risks associated with potential international business relationships could materially adversely affect our business
20. 20Collaboration arrangements we may enter into in the future may not be successful
21. 21Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations
22. 22We have and may in the future acquire businesses or products, or form strategic alliances in the future, and we may not realize the benefits of such acquisitions or alliances
23. 23We do not have any customer commitments
24. 24Our business and operations would suffer in the event of computer system failures, cyberattacks, or a deficiency in our cyber security
25. 25We may fail to manage growth successfully which may adversely impact operating results
26. 26Any products we develop will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the ability to obtain regulatory approval in a timely manner, or at all
27. 27We may not be able to obtain marketing approval
28. 28We rely on the protection of intellectual property rights
29. 29Intellectual property rights do not necessarily address all potential threats to our competitive advantage
30. 30the patents of others may harm our business
31. 31We may not be able to enforce our intellectual property rights throughout the world
32. 32Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate
33. 33Guidelines and recommendations published by various organizations can reduce the use of products that we may commercialize
34. 34Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our technology and products.
35. 35If we do not obtain protection under the Hatch-Waxman Amendments by obtaining data exclusivity, our business may be harmed
36. 36Risk of reduced or eliminated patent protection from non-compliance with regulatory requirements
37. 37We may infringe the intellectual property rights of others
38. 38require us to cease certain activities, including the sale of products
39. 39We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might harm our ability to develop and market our products
40. 40We may become involved in lawsuits to protect or enforce our patents or our other intellectual property rights, which could be expensive, time consuming and unsuccessful
41. 41Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities and have a harmful effect on the success of our business
42. 42Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties
43. 43We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms
44. 44We may be subject to claims arising from consultants or contractors misappropriating intellectual property
45. 45Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed
46. 46If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
47. 47The increasing use of artificial intelligence ("AI") and machine learning in drug discovery and development introduces new and evolving risks that could harm our business and competitive position
48. 48We use hazardous chemicals and biological materials in their business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly
49. 49If product liability lawsuits are brought against us then we may incur substantial liabilities and may be required to limit commercialization of the Products, if approved, and any other future products
50. 50exposure to adverse publicity
51. 51Our employees, independent contractors, principal investigators, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading, which could significantly harm our business
52. 52We may be unable to adequately prevent disclosure of trade secrets and other proprietary information
53. 53Lawsuits relating to intellectual property infringement will be costly and time consuming
54. 54Intellectual property disputes could distract our personnel from their normal responsibilities
55. 55Our directors may serve as directors of other biotech companies and may have conflicts of interest
56. 56Our business is affected by macroeconomic conditions
57. 57We may be responsible for corruption and anti-bribery law violations
58. 58We are subject to foreign exchange risks
59. 59We are subject to taxation risks and changing rules by different tax authorities or challenges to our tax positions
60. 60Our ability to use our net operating losses and certain other attributes may be subject to certain limitations
61. 61We are subject to a number of risks and hazards, of which not all of them may be sufficiently insured for

Risks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance

1. 62Coverage and reimbursement may be limited or unavailable in certain market segments for the Products, which could make it difficult for us to sell the Products profitably
2. 63The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products
3. 64Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations

Risks Relating to Our Securities

1. 65We may experience fluctuations in market value
2. 66Our securities could be subject to large price and volume volatility
3. 67Due to the relatively small size of our public float, our securities may experience extreme price volatility unrelated to our actual or expected operating performance, financial condition, or prospects, making it difficult for prospective investors to assess the rapidly changing value of our securities
4. 68Sales of a significant number of our common shares in the public markets, or the perception that such sales could occur, could depress the market price of our common shares
5. 69We will need to raise additional financing in the future and our shareholders may experience substantial dilution in the value of their investment if we issue additional common shares
6. 70We have in the past, and may in the future, issue debt and equity securities or securities convertible into equity securities, any of which may be senior to our common shares as to distributions and in liquidation, which could negatively affect the value of our common shares
7. 71We have no history of paying, and do not intend to pay, dividends on our common shares, so any returns will be substantially limited to the value of our common shares
8. 72We may issue, without shareholder approval, preferred shares that have rights and preferences potentially superior to those of our common shares
9. 73If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our common shares, the price of our securities could decline

Risks Related to Being a Public Company

1. 74If we are unable for any reason to meet the continued listing requirements of Nasdaq, such action or inaction could result in a delisting of our common shares and our Public Warrants, as applicable
2. 75There is a risk that we will fail to maintain an effective system of internal controls and our ability to produce timely and accurate financial statements or comply with applicable regulations could be adversely affected
3. 76We may be subject to securities litigation, which is expensive and could divert management attention